Poaster XV NATIONAL GeSIDA CONGRESS
Certificado participación GESIDACERTIFY THAT: Á. Ballesteros Magán, A. Tagarro, S. Domínguez-Rodríguez, W.C. Buck, V. Musiime, H.A. Mujuru, C. Chabala, J. Sacarlal, D. Nalwanga, T. [...]
Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change
Background Super-boosted lopinavir/ritonavir (LPV/r; ratio 4:4 instead of 4:1) is recommended for infants with HIV who are also receiving rifampicin-based tuberculosis (TB) treatment. However, due [...]
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia
Background This study assessed dolutegravir pharmacokinetics in HIV-infected infants receiving twice-daily (BID) dolutegravir with rifampicin-based tuberculosis (TB) treatment compared to once-daily (OD) dolutegravir without rifampicin. [...]
Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial
Background This study evaluated the pharmacokinetics of dolutegravir in HIV-infected infants receiving twice-daily (BID) dolutegravir with rifampicin-based tuberculosis (TB) treatment compared to once-daily (OD) dolutegravir [...]
EMPIRICAL Project’s 5th Annual Meeting Highlights Major Milestones and Future Plans
The 5th Annual Meeting of the EMPIRICAL Project was held on April 9-10, 2024, at the Novotel Hotel in Madrid. This significant event followed the [...]